Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note published on Friday, MarketBeat.com reports. The firm issued a buy rating and a $40.00 price objective on the stock.

Separately, Wedbush started coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They set an outperform rating and a $40.00 target price for the company.

Oruka Therapeutics Stock Up 4.1 %

Shares of ORKA stock opened at $25.90 on Friday. Oruka Therapeutics has a 12 month low of $18.72 and a 12 month high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.